AntiShock is developing a personalized fluid management system by continuous and non-invasive micro-hemodynamic monitoring.
Intravenous fluid administration is one of the most common interventions in medicine, and the cornerstone of treatment for a wide range of medical conditions, especially in critically ill patients. Uncontrolled fluid administration often leads to fluid overload which results in increased morbidity, mortality, and length of stay.
Blink is developing an independent energy and communication platform to power and connect smart ocular devices. BlinkIT™, our ergonomic smart patch situated on the eyelid, allows wireless charging and real-time data transfer between the ocular device and any smartphone.
That’s Blink Energy.
An AI-powered Layer of Inpatient Care to Predict, Detect and Prevent Delirium
CogMe aims to reduce cognitive drops in populations at risk, initially focusing on delirium in an inpatient setting. Using AI, CogMe will provide a comprehensive solution that will analyze cognitive and biological indicators of the individual patient to predict, detect and intervene to prevent cognitive drops.
Delirium, a prevalent and dangerous sudden state of confusion common in elderly adults, is nearly universally under-recognized and under-treated. This neuropsychiatric condition often leads to a cascade of events including mortality, patient falls, further complications, and increased utilization of extended care facilities.
Designed to guide healthcare providers in predicting the patient’s state, CogMe provides a scalable and sustainable holistic solution, including intervention, ongoing monitoring and management of patients’ condition to help providers make better informed clinical decisions, streamline patient care and significantly reduce costs.
Breaking the NGS Cost Barrier for Cancer Diagnostics
Breaking the NGS Cost Barrier for Cancer Diagnostics
Foresee Genomics has developed an innovative testing system for simultaneously identifying multiple cancer genomic markers, utilizing a revolutionary process that combines molecular biology and computational analysis.
Foresee Genomics elevates nanopore sequencing technology and will democratize NGS, making it available to any lab and anywhere.
GaitBetter promotes healthy aging by introducing a proprietary and clinically proven gait rehabilitation and falls prevention motor-cognitive training solution.
GaitBetter’s solution was shown to reduce the number of falls by 50% or more in research and in clinical use, with a lasting effect for months after training.
GaitBetter’s cognitive engagement add-on transforms any treadmill into a powerful motor-cognitive training device. The system is an ideal training in place solution for improving mobility for seniors and mobility impaired patients.
Gina Life Diagnostics is developing a novel smart test for the early detection of ovarian cancer.
Currently, no reliable test for early detection of ovarian cancer is available, resulting in extremely poor survival rates for most ovarian cancer patients, who are diagnosed at late stages of the disease when the disease has spread throughout the body and drugs do not work.
Gina Life is using biomarker fingerprint analysis within a digital health solution for the development of a home-use early detection test for ovarian cancer.
Gina Life expects to introduce its ground-breaking test for early detection of ovarian cancer by Q1 2022.
PRECISION MEDICINE AI PLATFORM TARGETING COMPLEX POLYGENIC DISEASES, BASED ON GENOMIC AND CLINICAL DATA
Our vision is that the OpenDNA precision medicine AI platform will allow physicians to replace trial and error treatment strategies with precision care at reduced cost.
Our first clinical application is cardiometabolic syndrome, affecting about 1 billion patients worldwide, which includes diabetes, hypertension, elevated cholesterol and obesity, and leads to major cardiovascular, kidney and other complications. People with cardiometabolic syndrome are twice as likely to die from cardiovascular disease, resulting in about 5 million deaths annually, and an economic burden of up to $73 billion in the US alone and $286 billion globally.
OpenDNA is in the process of validating its cardiometabolic syndrome solution in pilot studies, and then will apply the technology to other conditions such as cancer, autoimmune and musculoskeletal disease.
PG Medical Systems is harnessing state of the art machine learning algorithms and telehealth tools to bring together patients, primary care physicians (PCPs) and pain experts. Our platform empowers PCPs with a pain medicine toolbox, allowing pain diagnosis and treatment to reach every patient at the right time and in the right place, bringing pain treatment and management to a new level.
We envision our system will bridge an evident gap in pain medicine practice and improve treatment outcomes, while lowering the risks of addiction to prescription drugs.
Same shift, definitive antimicrobial susceptibility testing (AST)
phenofAST is developing definitive bacterial diagnostics that go from sample to results within hours. Current antimicrobial susceptibility testing (AST) methods have a 2-3 day turnaround, while the patients need treatment right now. This unfortunate situation forces doctors to prescribe antibiotics based on an educated guess. As a result, in the US alone, from 300 million antibiotic prescriptions given annually, 20% are the wrong antibiotic, 30% are unnecessary, and 70% are given for a longer time than needed.
phenofAST’s first product addresses UTIs, using proprietary optical technology and AI to produce definitive AST results directly from raw urine samples in only 4-6 hours. This game-changing turnaround time means that the clinical team can give the right antibiotic, right on time, leading to better outcomes and cost savings that can reach over $60,000 per patient.
Resmetrix Medical is developing a unique wearable respiratory monitoring system. A wearable chest strap that continuously and accurately monitors, records and analyses breathing patterns and alerts for early signs of deterioration in a patient’s clinical condition. The system provides a platform of respiratory disease management both for hospital and home use, enabling remote and home care respiratory monitoring for asthma, COPD, IPF, post anesthesia, and sleep apnea patients.
The company’s system can improve respiratory care and reduce healthcare costs by providing early signs of respiratory deterioration and personalizing treatment based on changes in respiratory patterns.
Sonaris provides autonomous ultrasound imaging anywhere without the need for a technician on site.
Our solution optimizes patients’ access to ultrasound scans in a variety of settings, such as the doctor’s office, pharmacy, self-test health kiosk, and even at the comfort of their own home, instead of being referred to an imaging center or a hospital.
Sonaris aims to bring ultrasound anywhere, anytime.
Intraocular pressure (IOP) is the most important and only known modifiable risk factor for the development of glaucoma. Almost 10% of the population age 40 and over have hyper IOP.
IOP fluctuates significantly throughout the course of a day and usually peak outside of clinic hours. Currently, IOP patients must visit their doctor for IOP tests, resulting in infrequent IOP measurements of only 3-4 times per year. These limited IOP measurements provide an incomplete clinical assessment of IOP and may inadequately assess disease treatment and prognosis for patients with glaucoma.
Tonomy provides a solution for constant self-monitoring of IOP at home, allowing a more complete assessment of patients’ IOP to determine the best course for managing these patients.
Cell and tissue sample mix-ups result in traumatic and life-threatening situations for patients and carry significant financial and reputational risk for practitioners and providers.
Verified Planet is developing a proprietary holistic IoT and software solution offering clinics and labs a customizable system for securing, documenting and tracing all sensitive biological sample transactions, ensuring no breach of protocol will be possible during sample journey and analyzing every sample interaction taking place.